Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Video library· Collaborative Drug Discovery, Inc.Audio: English

FDA Approvals of Aging Therapies: Status, Motivation & the Path to Eliminating Aging

Thumbnail from YouTube. Playing loads the YouTube player.

History & recommendationsOff

Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.

Up to 120 items · 90 days. Turning this off deletes the history.
Open saved items & history →

About this video

Creator description · original textText language: English

CDD Vault recently hosted the first webinar in our Longevity Webinar Series featuring Dr. Karl R. Pfleger (@karlpfleger), Founder of AgingBiotech.info. During the presentation, Dr. Pfleger explored how advances in geroscience, recent FDA approvals, and continued investment are accelerating the development of therapeutics that target the biology of aging rather than individual diseases. The discussion examined how the field has evolved from an emerging area of research into a rapidly growing biotechnology sector with expanding clinical programs, increasing regulatory momentum, and a growing ecosystem of companies working to extend healthy lifespan. You can view Dr. Pfleger's presentation slides here: https://www.collaborativedrug.com/hubfs/FDA%20Approvals%20of%20Aging%20Therapies%20Have%20Started_%20The%20Motivation%20for%2c%20Status%20of%2c%20%26%20Path%20to%20Eliminating%20Aging%20(1).pdf

Collaborative Drug Discovery, Inc. · 59 min · Source published: 2026-07-28

Added to Harbor: 10/23/2026

Original on YouTube ↗

Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…